Evidence map›Paper›PMID 22060063›Full record

ArticleNeurocase2012

Clinical characterization of bvFTD due to FUS neuropathology.

Suzee E Lee, William W Seeley, Pardis Poorzand, Rosa Rademakers, Anna Karydas, Christine M Stanley, Bruce L Miller, Katherine P Rankin

Abstract readCase Reports
In one paragraph

Article in Neurocase, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Understanding Theory of Mind-pragmatics relationship through the spectrum of neurodegenerative diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  5. Article
  6. Neuroimaging in Dementia.Seminars in neurology · 2017
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Acute lesions that impair affective empathy.Brain : a journal of neurology · 2013
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzee E LeeUniversity of California, San Francisco, Memory and Aging Center, San Francisco, CA 94143-1207, USA.
William W Seeley
Pardis Poorzand
Rosa Rademakers
Anna Karydas
Christine M Stanley
Bruce L Miller
Katherine P Rankin

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMAM01RR000079 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KESSLER, DAVID A · 1985 to 2006
$26.0M
Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4M
Measuring Altered Social Behavior in Neurodegenerative DiseaseR01AG029577 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RANKIN, KATHERINE P · 2008 to 2018
$3.6M
The genetics of chromosome 17q21-linked tau-negative FTDR01AG026251 · NIA · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2006 to 2014
$1.9M
Progranulin: Mutation and Regulation in Neurodegenerative diseaseR01NS065782 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2009 to 2012
$1.3M
Neuroanatomy of social Function in FTDK23AG021606 · NIA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI RANKIN, KATHERINE P · 2003 to 2005
$204k
NCRR NIH HHS GCRC-M01-RR00079NCRR NIH HHS M01 RR000079NIA NIH HHS AG023501NIA NIH HHS AG19724NIA NIH HHS K23 AG021606NIA NIH HHS K23-AG021606NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG026251NIA NIH HHS R01 AG029577NIA NIH HHS R01AG26251NIA NIH HHS T32 AG023481NIA NIH HHS T32AG23481NINDS NIH HHS R01 NS065782NINDS NIH HHS R01NS065782
6 · The paper itself

Abstract

In 2009, inclusions containing the fused in sarcoma (FUS) protein were identified as a third major molecular class of pathology underlying the behavioral variant frontotemporal dementia (bvFTD) syndrome. Due to the low prevalence of FUS pathology, few clinical descriptions have been published and none provides information about specific social-emotional deficits despite evidence for severe behavioral manifestations in this disorder. We evaluated a patient with bvFTD due to FUS pathology using a comprehensive battery of cognitive and social- emotional tests. A structural MRI scan and genetic tests for tau, progranulin, and FUS mutations were also performed. The patient showed preserved general cognitive functioning and superior working memory, but severe deficits in emotion attribution, sensitivity to punishment, and diminished capacity for interpersonal warmth and empathy. The gray matter atrophy pattern corresponded to this focal deficit profile, with preservation of dorsolateral fronto-parietal regions associated with executive functioning but severe damage to right worse than left frontoinsula, temporal pole, subgenual anterior cingulate, medial orbitofrontal cortex, amygdala, and caudate. This patient demonstrates the striking focality associated with FUS neuropathology in patients with bvFTD.

Indexed as

AdultAutopsyBehaviorBrainDecision MakingDepressionExecutive FunctionFatal OutcomeFrontotemporal DementiaHumansImpulsive BehaviorLanguageMagnetic Resonance ImagingMaleMiddle AgedNeurologic ExaminationRNA-Binding Protein FUS

Identifiers

PMID22060063
PMCPMC3288419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.